戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d to 49% after 3 cycles (P < .001 vs cycle 1 hypericin).
2 the administration of emodin, a precursor of hypericin.
3 hemotherapeutic agents 8-methoxypsoralen and hypericin.
4  the dark to minimize photoactivation of the hypericin.
5 e of pseudohypericin (0.135-3.280 mug/g) and hypericin (0.277-6.634 mug/g) in all the oils, whereas c
6                           UVA-photoactivated hypericin (0.5-2.0 J per cm2) could also inhibit prolife
7                                  Intravenous hypericin, 0.25 or 0.5 mg/kg of body weight twice weekly
8 ly or 0.25 mg/kg three times weekly, or oral hypericin, 0.5 mg/kg daily.
9  intravenously injected with (64)Cu-bis-DOTA-hypericin (24 h after laser treatment in treated mice).
10 3-acetate and inhibited by staurosporine and hypericin, a drug with potent anti-HIV activity.
11                                              Hypericin, a photosensitive and red-colored naphthodiant
12                                      In vivo Hypericin and Foscan mediated PDT, using cancer xenograf
13                                              Hypericin and pseudohypericin were common in the active
14 cence agents (hexylester aminolevulinate and hypericin) and their application to flexible cystoscopy.
15 cycles of hypericin PDT (P < .001 vs cycle 1 hypericin) and to 49% after 3 cycles (P < .001 vs cycle
16 l cultures revealed the gene responsible for hypericin biosynthesis after the administration of emodi
17 trations of K-252a, K-252b, calphostin C and hypericin caused less than 20 % inhibition.
18                                              Hypericin caused significant phototoxicity and had no an
19              The affinity of (64)Cu-bis-DOTA-hypericin for injured tissues may be attributed to the b
20 plasmon resonance study showed that bis-DOTA-hypericin had higher binding affinity to phosphatidylser
21                              (64)Cu-bis-DOTA-hypericin has a potential to image thermal therapy-induc
22                                              Hypericin (Hy) is a potent lipid-soluble photosensitiser
23       A major gene termed Hyp-1 encoding for hypericin (HyH) biosynthesis was cloned and characterize
24                         The incorporation of hypericin (Hyp) from aqueous solutions into giant unilam
25                                              Hypericin (HYP) is a major constituent of the herbal ant
26 all-molecular-weight (64)Cu-labeled bis-DOTA-hypericin in the noninvasive assessment of response to p
27 MCs to photoactivated 8-methoxypsoralen- and hypericin-induced apoptosis.
28  part, one mechanism by which photoactivated hypericin inhibits malignant T cell proliferation.
29                     These data indicate that hypericin inhibits mitogen-induced proliferation of mali
30                                              Hypericin is a photodynamic compound activated by either
31                                              Hypericin is a promising new agent that has excellent se
32 300 mg of H. perforatum standardized to 0.3% hypericin (n = 27) or a matched placebo (n = 27) 3 times
33                            Topical synthetic hypericin ointment, 0.25%, activated with visible light
34 ions were incubated with serial dilutions of hypericin or 8-methoxypsoralen and then stimulated with
35 e 1, patients were randomized 2:1 to receive hypericin or placebo to 3 index lesions twice weekly for
36  to 40% in patients who received 2 cycles of hypericin PDT (P < .001 vs cycle 1 hypericin) and to 49%
37 mized clinical trial indicate that synthetic hypericin PDT is effective in early-stage patch and plaq
38                  After 6 weeks of treatment, hypericin PDT was more effective than placebo (cycle 1 I
39                                              Hypericin, photoactivated with 1.1-3.3 J white light per
40                                              Hypericin, photoactivated with either UVA or white light
41 iking example of protein-specific effects on hypericin photodynamic activity.
42 cells had a higher uptake of (64)Cu-bis-DOTA-hypericin than nontreated cells.
43                              (64)Cu-bis-DOTA-hypericin uptake was significantly higher in the treatme
44 eration is dependent on the concentration of hypericin used and the dose of light required to photoac
45                               In this study, hypericin was found to inhibit proliferative responses o
46                                     Bis-DOTA-hypericin was labeled with (64)Cu with high efficiency (
47 hat bioactive polycyclic quinones related to hypericin were, and still are, globally widespread in po
48 rther screened for biosynthesis of emodin to hypericin, which resulted in an 84.6% conversion.